COMP <GO>
RVMD vs BIIB // RETURN ON INVESTED CAPITAL (ROIC)
Revolution Medicines Inc. (NASDAQ) VS. Biogen Inc. (NASDAQ) • 15-METRIC TALLY: RVMD 3
— BIIB 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: BIIB
LAST: $191.31 (+0.55%) • MKT CAP: $40.78B
roic
-28.60%
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
roic
6.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. BIIB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | BIIB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 75.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.60% | 6.40% | -35.00 | BIIB | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 22.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 5.56% | -7.80 | BIIB | /fcf-yield <GO> |
| Operating Margin | — | 15.90% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 13.10% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 2.20% | +13.20 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.70 | +22.30 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | BIIB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 61.8 | -14.00 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.10 | -0.03 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 26.5x | +7.50 | BIIB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $36.90B | $3.88B | RVMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | BIIB REV | RVMD GROSS % | BIIB GROSS % | RVMD FCF | BIIB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $9.89B | — | 75.7% | -$913.7M | $2.05B |
| FY 2024 | $0 | $9.68B | — | 76.1% | -$567.7M | $2.72B |
| FY 2023 | $11.6M | $9.84B | — | — | -$351.1M | $1.10B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
BIIB // BETA 1.10